KAZ954 / Novartis - LARVOL DELTA

KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=77 | Terminated | Sponsor: Novartis Pharmaceuticals | Active, not recruiting ➔ Terminated; Business reasons

Combination therapy • IO biomarker • Metastases • Trial termination • Oncology • Solid Tumor • PD-L1

Determining the mechanism of action of the anti-ENTPD2 antibody, KAZ954* (AACR-NCI-EORTC 2023) - No abstract available

Oncology

KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=77 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals | Recruiting ➔ Active, not recruiting | N=145 ➔ 77

Combination therapy • Enrollment change • Enrollment closed • IO biomarker • Metastases • Oncology • Solid Tumor • PD-L1

A Phase 1/1b study of KAZ954 alone and in combination with spartalizumab (PDR001) and taminadenant (NIR178) in patients with advanced gastrointestinal malignancies. (AACR-NCI-EORTC 2023) - No abstract available

Clinical • Combination therapy • Metastases • P1 data • Gastrointestinal Cancer • Oncology

Determining the Mechanism of Action of the Anti-ENTPD2 Antibody, KAZ954. (AACR-NCI-EORTC 2023) - No abstract available

Oncology

KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=145 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Feb 2025 ➔ Sep 2023 | Trial primary completion date: Feb 2025 ➔ Sep 2023

Combination therapy • IO biomarker • Metastases • Trial completion date • Trial primary completion date • Oncology • Solid Tumor • PD-L1

KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=145 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Aug 2024 ➔ Feb 2025 | Trial primary completion date: Aug 2024 ➔ Feb 2025

Combination therapy • IO biomarker • Metastases • Trial completion date • Trial primary completion date • Oncology • Solid Tumor • PD-L1

KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors (clinicaltrials.gov) - P1; N=145; Recruiting; Sponsor: Novartis Pharmaceuticals; Not yet recruiting ➔ Recruiting

Clinical • Combination therapy • Enrollment open • Oncology • Solid Tumor

KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors (clinicaltrials.gov) - P1; N=145; Not yet recruiting; Sponsor: Novartis Pharmaceuticals

Clinical • Combination therapy • New P1 trial